# reload+after+2024-01-21 09:46:56.810246
address1§2080 Century Park East
address2§Suite 906
city§Los Angeles
state§CA
zip§90067
country§United States
phone§305 918 1980
website§https://www.renovarobio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
fullTimeEmployees§12
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Mark R. Dybul M.D.', 'age': 60, 'title': 'CEO, Director & Member of HBV Scientific Advisory Board', 'yearBorn': 1963, 'fiscalYear': 2023, 'totalPay': 764583, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Luisa  Puche', 'age': 59, 'title': 'CFO & Corporate Secretary', 'yearBorn': 1964, 'fiscalYear': 2023, 'totalPay': 510000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Francois  Binette M.Sc., Ph.D.', 'age': 59, 'title': 'COO and Executive VP for Research & Development', 'yearBorn': 1964, 'fiscalYear': 2023, 'totalPay': 504375, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Serhat  Gümrükcü', 'title': 'Co-Founder & Inventor', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Greg  Duczynski Ph.D.', 'title': 'Senior Vice President for Clinical Operations', 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.318
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§Renovaro Biosciences Inc.
longName§Renovaro Biosciences Inc.
firstTradeDateEpochUtc§1518013800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§76ebd049-a1b1-3adf-8f9d-dc581ba8ef18
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§0.052
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
